Moberg Pharma AB (publ) (MOB.ST)
SEK 7.95
(2.65%)
SEK 7.95
(2.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.09 Million SEK | 11.62% |
| 2022 | -2.37 Million SEK | 8.09% |
| 2021 | -2.58 Million SEK | -107.68% |
| 2020 | 33.65 Million SEK | 0.0% |
| 2018 | 334.6 Million SEK | 6.61% |
| 2017 | 313.85 Million SEK | 34.73% |
| 2016 | 232.94 Million SEK | 9.04% |
| 2015 | 213.64 Million SEK | 41.38% |
| 2014 | 151.11 Million SEK | 28.69% |
| 2013 | 117.42 Million SEK | 34.06% |
| 2012 | 87.59 Million SEK | 122.81% |
| 2011 | 39.31 Million SEK | 594.27% |
| 2010 | 5.66 Million SEK | 250.33% |
| 2009 | 1.61 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.72 Million SEK | 453.05% |
| 2024 Q1 | 492 Thousand SEK | 289.23% |
| 2023 Q3 | -613 Thousand SEK | 0.0% |
| 2023 Q1 | -613 Thousand SEK | 42.98% |
| 2023 FY | -2.09 Million SEK | 11.62% |
| 2023 Q2 | -613 Thousand SEK | 0.0% |
| 2023 Q4 | -260 Thousand SEK | 57.59% |
| 2022 Q2 | -646 Thousand SEK | -0.16% |
| 2022 Q1 | -645 Thousand SEK | -232.47% |
| 2022 FY | -2.37 Million SEK | 8.09% |
| 2022 Q3 | -439 Thousand SEK | 32.04% |
| 2022 Q4 | -1.07 Million SEK | -144.87% |
| 2021 FY | -2.58 Million SEK | -107.68% |
| 2021 Q4 | -194 Thousand SEK | 10.19% |
| 2021 Q1 | -263 Thousand SEK | 98.44% |
| 2021 Q2 | -215 Thousand SEK | 18.25% |
| 2021 Q3 | -216 Thousand SEK | -0.47% |
| 2020 FY | 33.65 Million SEK | 0.0% |
| 2020 Q1 | 47.81 Million SEK | 1691.64% |
| 2020 Q4 | -16.82 Million SEK | 0.0% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | 2.66 Million SEK | -94.42% |
| 2019 Q1 | 15.55 Million SEK | -78.66% |
| 2019 Q3 | 47.81 Million SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2018 Q2 | 110.41 Million SEK | 64.24% |
| 2018 FY | 334.6 Million SEK | 6.61% |
| 2018 Q4 | 72.87 Million SEK | -13.33% |
| 2018 Q3 | 84.08 Million SEK | -23.84% |
| 2018 Q1 | 67.22 Million SEK | 2.97% |
| 2017 Q3 | 76.94 Million SEK | -22.12% |
| 2017 FY | 313.85 Million SEK | 34.73% |
| 2017 Q1 | 72.83 Million SEK | 19.66% |
| 2017 Q4 | 65.28 Million SEK | -15.15% |
| 2017 Q2 | 98.79 Million SEK | 35.64% |
| 2016 FY | 232.94 Million SEK | 9.04% |
| 2016 Q1 | 48.84 Million SEK | 33.02% |
| 2016 Q2 | 51.21 Million SEK | 4.85% |
| 2016 Q3 | 72.01 Million SEK | 40.61% |
| 2016 Q4 | 60.86 Million SEK | -15.48% |
| 2015 FY | 213.64 Million SEK | 41.38% |
| 2015 Q1 | 56.75 Million SEK | 76.06% |
| 2015 Q3 | 48.66 Million SEK | -31.94% |
| 2015 Q2 | 71.5 Million SEK | 26.0% |
| 2015 Q4 | 36.72 Million SEK | -24.54% |
| 2014 Q4 | 32.23 Million SEK | -10.88% |
| 2014 Q2 | 44.78 Million SEK | 18.1% |
| 2014 Q1 | 37.92 Million SEK | 39.05% |
| 2014 FY | 151.11 Million SEK | 28.69% |
| 2014 Q3 | 36.17 Million SEK | -19.24% |
| 2013 FY | 117.42 Million SEK | 34.06% |
| 2013 Q4 | 27.27 Million SEK | -1.92% |
| 2013 Q3 | 27.8 Million SEK | -24.78% |
| 2013 Q2 | 36.96 Million SEK | 45.67% |
| 2013 Q1 | 25.37 Million SEK | 10.75% |
| 2012 Q2 | 18.08 Million SEK | -28.89% |
| 2012 Q1 | 25.43 Million SEK | 54.3% |
| 2012 FY | 87.59 Million SEK | 122.81% |
| 2012 Q4 | 22.91 Million SEK | 8.29% |
| 2012 Q3 | 21.16 Million SEK | 17.01% |
| 2011 Q2 | 3.67 Million SEK | 47.22% |
| 2011 Q4 | 16.48 Million SEK | -1.11% |
| 2011 Q3 | 16.66 Million SEK | 354.02% |
| 2011 Q1 | 2.49 Million SEK | -24.8% |
| 2011 FY | 39.31 Million SEK | 594.27% |
| 2010 Q1 | 603.98 Thousand SEK | 0.0% |
| 2010 FY | 5.66 Million SEK | 250.33% |
| 2010 Q3 | 1.58 Million SEK | 894.13% |
| 2010 Q4 | 3.31 Million SEK | 109.39% |
| 2010 Q2 | 159.28 Thousand SEK | -73.63% |
| 2009 FY | 1.61 Million SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | 131.842% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | -340.966% |
| BioGaia AB (publ) | 950.19 Million SEK | 100.221% |
| Enzymatica AB (publ) | 31.86 Million SEK | 106.588% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 46.193% |
| Gabather AB (publ) | - SEK | Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | -23222.222% |
| Nanexa AB (publ) | 59.15 Million SEK | 103.548% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 113.092% |
| ODI Pharma AB | -1.34 Million SEK | -56.451% |
| Orexo AB (publ) | 549.9 Million SEK | 100.382% |
| Probi AB (publ) | 220.21 Million SEK | 100.953% |
| Swedencare AB (publ) | 164.8 Million SEK | 101.274% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 100.015% |
| Toleranzia AB | -919 Thousand SEK | -128.4% |
| Vivesto AB | -10.65 Million SEK | 80.302% |